Latest Iovance Biotherapeutics News & Updates

See the latest news and media coverage for Iovance. We track all announcements, press releases, and industry mentions in real time, all in one place.

Iovance Biotherapeutics (Iovance)

Biopharmaceutical company developing and commercializing cancer immunotherapies

iovance.com

Headquarters: San Carlos, United States
Founded year: 2007
Company type: Public company
Number of employees: 900–1,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Iovance Biotherapeutics (Iovance)

In short: Iovance achieved record $99M Q2 2026 revenue, secured international Amtagvi approvals, and advanced its TIL therapy pipeline.

Company announcements

August 6 Iovance

Iovance reports record second quarter 2026 revenue of ~$99M

Total revenue increased 66% year-over-year, gross margin reached 56%, and FDA granted Fast Track for lifileucel in soft tissue sarcomas.

June 5 Iovance

Iovance Biotherapeutics announces FDA clearance for IOV-5001 IND

The next-generation IL-12 tethered TIL therapy will be evaluated in a Phase 1/2 basket trial for advanced solid tumors, with enrollment starting in H2 2026.

June 3 Iovance

Iovance's Amtagvi granted approval for advanced melanoma in Australia

The Therapeutic Goods Administration approved the tumor-derived autologous T cell immunotherapy for previously treated advanced melanoma, marking Iovance's third marketing authorization.

May 7 Iovance

Iovance reports Q1 2026 revenue growth of 45%

The company guides Q2 2026 revenue to $86-88M and full-year to $350-370M, with a 40% confirmed response rate in endometrial cancer.

Media coverage

August 27 Medscape

How Safe Is Lifileucel After Patients Go Home?

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

August 20 RTTNews

Top Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%,...

Biotech stocks advanced on strong quarterly results and pipeline updates. DERM gained on 23% revenue growth and rising Emrosi adoption, while IOVA posted record $99.

August 20 Yahoo Finance

Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says

Iovance Biotherapeutics' (IOVA) pace of growth remains uncertain as Amtagvi, its cell therapy for advanced melanoma, faces competitive pressure and slow onboarding at authorized t...

August 19 Yahoo Finance

IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally?

IOVA’s rally coincides with positive sentiment across melanoma-focused biotech stocks after Merck an...

Never miss news about Iovance

Track Iovance and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Iovance competitors & trending companies

Browse news for competitors to Iovance and other trending companies.